How Often Should Lurbinectedin Side Effects Be Monitored?
Lurbinectedin treatment requires close monitoring for potential side effects, particularly neutropenia, anemia, and thrombocytopenia, which can occur at any point during therapy [1].
What Are the Main Side Effects of Lurbinectedin?
The primary side effects of lurbinectedin include myelosuppression, such as neutropenia, anemia, and thrombocytopenia [1]. Other reported side effects encompass fatigue, nausea, vomiting, diarrhea, decreased appetite, dyspnea, and elevated liver enzymes [1].
How is Lurbinectedin Administered?
Lurbinectedin is administered intravenously as a 30-minute infusion every three weeks [1].
What Clinical Trials Have Evaluated Lurbinectedin?
Lurbinectedin has been studied in various clinical trials. A Phase II study for patients with relapsed small cell lung cancer showed a response rate of 35% and a median overall survival of 9.3 months [1]. A Phase III trial, the ATLANTIS study, investigated lurbinectedin in combination with etoposide versus etoposide alone in the second-line treatment of small cell lung cancer, but did not meet its primary endpoint for overall survival [2]. However, subgroup analyses of the ATLANTIS study suggested potential benefit in certain patient populations [2].
What Regulatory Status Does Lurbinectedin Hold?
Lurbinectedin received accelerated approval from the U.S. Food and Drug Administration (FDA) in June 2020 for adult patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy [3].
What Are the Next Steps for Lurbinectedin's Approval?
Following the FDA's accelerated approval, the manufacturer was required to conduct post-marketing studies to confirm clinical benefit [3]. The outcome of these confirmatory trials will determine the continued availability of lurbinectedin.
Sources:
[1] https://www.oncolife.com/news/new-drug-approvals/drug-approval-lurbinectedin-for-small-cell-lung-cancer
[2] https://www.mskcc.org/news/lurbinectedin-treatment-small-cell-lung-cancer-fail-meet-primary-endpoint-phase-3-trial
[3] https://www.fda.gov/drugs/drug-approvals/fda-approves-lurbinectedin-metastatic-small-cell-lung-cancer